chr9-128580928-G-A

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_001130438.3(SPTAN1):​c.1330G>A​(p.Val444Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00312 in 1,612,962 control chromosomes in the GnomAD database, including 142 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V444L) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0028 ( 10 hom., cov: 31)
Exomes 𝑓: 0.0032 ( 132 hom. )

Consequence

SPTAN1
NM_001130438.3 missense

Scores

18

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts P:1U:1B:8

Conservation

PhyloP100: -0.0890

Publications

8 publications found
Variant links:
Genes affected
SPTAN1 (HGNC:11273): (spectrin alpha, non-erythrocytic 1) Spectrins are a family of filamentous cytoskeletal proteins that function as essential scaffold proteins that stabilize the plasma membrane and organize intracellular organelles. Spectrins are composed of alpha and beta dimers that associate to form tetramers linked in a head-to-head arrangement. This gene encodes an alpha spectrin that is specifically expressed in nonerythrocytic cells. The encoded protein has been implicated in other cellular functions including DNA repair and cell cycle regulation. Mutations in this gene are the cause of early infantile epileptic encephalopathy-5. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010]
SPTAN1 Gene-Disease associations (from GenCC):
  • developmental and epileptic encephalopathy, 5
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Ambry Genetics, Labcorp Genetics (formerly Invitae), Laboratory for Molecular Medicine
  • genetic developmental and epileptic encephalopathy
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • infantile spasms
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.004676819).
BP6
Variant 9-128580928-G-A is Benign according to our data. Variant chr9-128580928-G-A is described in ClinVar as Benign. ClinVar VariationId is 139269.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAdExome4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.0516 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SPTAN1NM_001130438.3 linkc.1330G>A p.Val444Ile missense_variant Exon 11 of 57 ENST00000372739.7 NP_001123910.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SPTAN1ENST00000372739.7 linkc.1330G>A p.Val444Ile missense_variant Exon 11 of 57 1 NM_001130438.3 ENSP00000361824.4

Frequencies

GnomAD3 genomes
AF:
0.00281
AC:
428
AN:
152194
Hom.:
9
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.000772
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000458
Gnomad ASJ
AF:
0.00519
Gnomad EAS
AF:
0.0407
Gnomad SAS
AF:
0.0275
Gnomad FIN
AF:
0.000753
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000176
Gnomad OTH
AF:
0.00336
GnomAD2 exomes
AF:
0.00522
AC:
1311
AN:
251106
AF XY:
0.00581
show subpopulations
Gnomad AFR exome
AF:
0.000800
Gnomad AMR exome
AF:
0.000405
Gnomad ASJ exome
AF:
0.00536
Gnomad EAS exome
AF:
0.0290
Gnomad FIN exome
AF:
0.000187
Gnomad NFE exome
AF:
0.000255
Gnomad OTH exome
AF:
0.00554
GnomAD4 exome
AF:
0.00315
AC:
4604
AN:
1460650
Hom.:
132
Cov.:
31
AF XY:
0.00363
AC XY:
2635
AN XY:
726642
show subpopulations
African (AFR)
AF:
0.000628
AC:
21
AN:
33444
American (AMR)
AF:
0.000313
AC:
14
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00513
AC:
134
AN:
26132
East Asian (EAS)
AF:
0.0535
AC:
2123
AN:
39696
South Asian (SAS)
AF:
0.0208
AC:
1789
AN:
86200
European-Finnish (FIN)
AF:
0.000150
AC:
8
AN:
53220
Middle Eastern (MID)
AF:
0.00222
AC:
11
AN:
4944
European-Non Finnish (NFE)
AF:
0.000185
AC:
206
AN:
1111992
Other (OTH)
AF:
0.00494
AC:
298
AN:
60298
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.476
Heterozygous variant carriers
0
277
554
830
1107
1384
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
60
120
180
240
300
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00282
AC:
430
AN:
152312
Hom.:
10
Cov.:
31
AF XY:
0.00332
AC XY:
247
AN XY:
74464
show subpopulations
African (AFR)
AF:
0.000770
AC:
32
AN:
41572
American (AMR)
AF:
0.000457
AC:
7
AN:
15304
Ashkenazi Jewish (ASJ)
AF:
0.00519
AC:
18
AN:
3470
East Asian (EAS)
AF:
0.0404
AC:
209
AN:
5174
South Asian (SAS)
AF:
0.0282
AC:
136
AN:
4828
European-Finnish (FIN)
AF:
0.000753
AC:
8
AN:
10618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.000176
AC:
12
AN:
68036
Other (OTH)
AF:
0.00380
AC:
8
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
18
36
54
72
90
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00144
Hom.:
10
Bravo
AF:
0.00165
TwinsUK
AF:
0.00
AC:
0
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.000908
AC:
4
ESP6500EA
AF:
0.000465
AC:
4
ExAC
AF:
0.00566
AC:
687
Asia WGS
AF:
0.0520
AC:
181
AN:
3478
EpiCase
AF:
0.000382
EpiControl
AF:
0.000119

ClinVar

Significance: Benign
Submissions summary: Pathogenic:1Uncertain:1Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2
Nov 16, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 26539891, 31180159) -

-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Jun 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SPTAN1: BP4, BS1, BS2 -

not specified Benign:2
Feb 08, 2016
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 19, 2015
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Developmental and epileptic encephalopathy, 5 Benign:2
Jul 15, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

May 28, 2019
Mendelics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Abnormal brain morphology Pathogenic:1
-
Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine
Significance:Likely pathogenic
Review Status:flagged submission
Collection Method:research

- -

Inborn genetic diseases Benign:1
Feb 10, 2017
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Developmental and epileptic encephalopathy Benign:1
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.055
BayesDel_addAF
Benign
-0.71
T
BayesDel_noAF
Benign
-0.73
CADD
Benign
0.013
DANN
Benign
0.83
DEOGEN2
Benign
0.096
T;.;.;.;.
Eigen
Benign
-1.8
Eigen_PC
Benign
-1.8
FATHMM_MKL
Benign
0.030
N
LIST_S2
Benign
0.59
T;T;T;T;T
MetaRNN
Benign
0.0047
T;T;T;T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
-0.90
N;.;N;N;.
PhyloP100
-0.089
PrimateAI
Benign
0.26
T
PROVEAN
Benign
-0.23
N;.;N;N;.
REVEL
Benign
0.038
Sift
Benign
0.66
T;.;T;T;.
Sift4G
Benign
0.35
T;T;T;T;T
Polyphen
0.0010
B;.;B;B;.
Vest4
0.52
MVP
0.17
MPC
0.63
ClinPred
0.0034
T
GERP RS
-11
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.015
gMVP
0.017
Mutation Taster
=94/6
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs77358650; hg19: chr9-131343207; COSMIC: COSV63987177; COSMIC: COSV63987177; API